Aktienanalyse zu Xeris Biopharma Holdings Inc (XERS)XERSXeris Biopharma Holdings Inc

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xeris Biopharma Holdings Inc is a good buy right now due to its recent revenue growth of 28.7% year-over-year, reaching $92 million in Q2 2026, and a gross margin improvement to 87%. However, the company reported a widened net loss of $28.9 million, which is a significant risk. The current price of $8.48 is below the analyst price target of $12, suggesting potential upside.

4 analysts cover XERS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.67.